Drug Utilization Review (DUR) Meeting Minutes
June 14, 2010

Members Present: Norman Byers, Carrie Sorenson, Jeffrey Hostetter, John Savageau, Carlotta McCleary, David Clinkenbeard, Russ Sobotta, Cheryl Huber
Members Absent: Kim Krohn, James Carlson, Steve Irsfeld, Greg Pfister, Patricia Churchill, Leann Ness, Todd Twogood
Medicaid Pharmacy Department: Brendan Joyce, Gary Betting
HID Staff Present: Candace Rieth

Chair, J. Hostetter called the meeting to order at 1:00 pm. Chair, J. Hostetter asked for a motion to approve the minutes from the March meeting. C. Huber moved that the minutes be approved and J. Savageau seconded the motion. Chair, J. Hostetter called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update
B. Joyce informed the board that the department is currently putting together the budget for the next biennium. Enrollment is estimated to be approximately 62,700. This number does not include any changes in enrollment due to Health Care Reform.

Xolair Review
B. Joyce reviewed Xolair utilization. At the March meeting, the board suggested that Xolair have a patient safety model similar to hemophilia to ensure compliance. The board reviewed the prior authorization form that was included in the DUR Pack and made a recommendation that a box be included on the form asking for the specialist involved in treatment. C. Sorenson asked that 'serum' be added to the form before IgE. N. Byers made a motion to place Xolair on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

Specialty Medication Review
In March, the board asked that a review of all specialty medications suitable for criteria based prior authorizations be reviewed and presented with Xolair at the next board meeting. A list of commonly prior authorized medications was included in the DUR pack. The committee recommended that two meetings be held for each specialty drug considered for prior authorization. The department will review the list and include specialty medications on future agendas.

Suboxone/Subutex Review
A motion and second were made at the March meeting to place Suboxone and Subutex on prior authorization. The topic was brought up for a second review. Brendan reviewed Suboxone and Subutex utilization with the board. There was no public comment. After discussion, Chair, J. Hostetter called for a voice vote to approve the motion. The motion passed with no audible dissent.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Sedative/Hypnotics, Qualaquin, ACE-Inhibitors, ARBs, Renin Inhibitors, Synagis, Growth Hormone, and Triptan forms and criteria were reviewed. C. Rieth gave an update on Synagis utilization for the 2009/2010 season. Dr. Patel spoke regarding the registration process and informed the board that the process worked well this season.

Ampyra Review
B. Joyce reviewed Ampyra information with the Board. A letter from the National MS Society was circulated to Board members asking that minimal restrictions be placed on Ampyra. Brian Hutchinson of Acorda Therapeutics spoke to the committee regarding Ampyra. A motion was made by N. Byers to place Ampyra on prior authorization with a neurologist involved in therapy. C. Huber seconded the motion. This topic will be brought up at the next meeting for finalization.

Ribapak Review
B. Joyce reviewed Ribapak utilization with the Board. There was no public comment. After discussion, J. Savageau made a motion to place Ribapak on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

Emla Review
B. Joyce reviewed Emla utilization with the Board. There was no public comment. After discussion, N. Byers made a motion to place Emla on prior authorization. C. Huber seconded the motion. This topic will be brought up at the next meeting for finalization.

Narcotic Review
B. Joyce reviewed narcotic utilization with the Board. There was no public comment. After discussion, C. Sorenson made a motion that name brand narcotic and tramadol prior authorization forms are brought to the board for approval. N. Byers seconded the motion. This topic will be brought up at the next meeting for finalization.

Metozolv Review
B. Joyce reviewed Metozolv information with the Board. There was no public comment. After discussion, N. Byers made a motion to place Metozolv on prior authorization. C. Huber seconded the motion. This topic will be brought up at the next meeting for finalization.

Intuniv Review
Brendan reviewed Intuniv utilization in North Dakota. At the March meeting, the board asked that additional information be brought to the next meeting including the specialty of providers currently prescribing Intuniv as well as any studies of guanfacine IR in children that are available. Studies were sent to the board members after the March meeting. C. McCleary asked for clarification on current legislation that states that stimulant medications for ADD/ADHD cannot be placed on prior authorization and the potential that legislative intent could have been that no ADHD medications should be placed on prior authorization. Since Intuniv is not a stimulant medication, it doesn't fall under the letter of the law, but B. Joyce informed the Board that legislative intent would be researched by the Department's legal staff prior to any implementation of prior authorization on this drug if the DUR Board recommended prior authorizing this drug. There was no public comment. J. Savageau made a motion to place Intuniv on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. C. Huber moved to approve the new criteria and C. Sorenson seconded the motion. Chair, J. Hostetter called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held September 13, 2010. C. Huber made a motion to adjourn the meeting. C. Sorenson seconded. The motion passed with no audible dissent. Chair J. Hostetter adjourned the meeting at 3pm.